Reed I Ayabe1, Michael Wach1, Samantha Ruff1, Sean Martin1, Laurence Diggs2, Timothy Wiemken3, Leslie Hinyard3, Jeremy L Davis1, Carrie Luu2, Jonathan M Hernandez4. 1. Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 2. Division of General Surgery, Department of Surgery, Saint Louis University Hospital, St. Louis, MO, USA. 3. Saint Louis University Center for Health Outcomes Research (SLUCOR), St. Louis, MO, USA. 4. Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. jonathan.hernandez@nih.gov.
Abstract
BACKGROUND: Primary gallbladder neuroendocrine tumors (NETs) are rare, poorly understood cancers infrequently encountered at even the largest of tertiary referral centers. We therefore sought to identify a large cohort of patients with gallbladder NETs using a national database, with the aim of defining treatment modalities employed and survival associated with these uncommon malignancies. METHODS: Patients with primary gallbladder NETs were identified in the National Cancer Database, and clinicopathologic characteristics were recorded. A univariate log-rank survival analysis was completed for patients who underwent resection. Parameters found to be significant were entered into a multivariate accelerated failure time analysis. For context, survival comparisons were included for patients who underwent resections for NETs at any gastrointestinal site and for gallbladder adenocarcinoma. RESULTS: Overall, 754 patients with gallbladder NETs were identified. Patients were predominantly female (n = 518, 69%), White (n = 503, 67%), presented with stage IV disease (n = 295, 39%) and had high-grade lesions (n = 312, 41%). The majority underwent resection (n = 480, 64%), primarily simple cholecystectomy (n = 431, 90%), whereas a minority received multimodal therapy (n = 145, 21%). Among patients who underwent resection, older age (p = 0.001), large cell histology (p = 0.012), and positive margins (p = 0.030) were independently associated with worse overall survival. Patients with gallbladder NETs had improved survival relative to those with gallbladder adenocarcinoma (p = 0.001), but significantly worse survival than patients with NETs from other gastrointestinal sites (p < 0.001). CONCLUSIONS: Primary gallbladder NETs are aggressive lesions that carry a worse prognosis than NETs of other gastrointestinal sites. Older age, positive margins, and large cell histology are associated with abbreviated survival after resection.
BACKGROUND:Primary gallbladder neuroendocrine tumors (NETs) are rare, poorly understood cancers infrequently encountered at even the largest of tertiary referral centers. We therefore sought to identify a large cohort of patients with gallbladder NETs using a national database, with the aim of defining treatment modalities employed and survival associated with these uncommon malignancies. METHODS:Patients with primary gallbladder NETs were identified in the National Cancer Database, and clinicopathologic characteristics were recorded. A univariate log-rank survival analysis was completed for patients who underwent resection. Parameters found to be significant were entered into a multivariate accelerated failure time analysis. For context, survival comparisons were included for patients who underwent resections for NETs at any gastrointestinal site and for gallbladder adenocarcinoma. RESULTS: Overall, 754 patients with gallbladder NETs were identified. Patients were predominantly female (n = 518, 69%), White (n = 503, 67%), presented with stage IV disease (n = 295, 39%) and had high-grade lesions (n = 312, 41%). The majority underwent resection (n = 480, 64%), primarily simple cholecystectomy (n = 431, 90%), whereas a minority received multimodal therapy (n = 145, 21%). Among patients who underwent resection, older age (p = 0.001), large cell histology (p = 0.012), and positive margins (p = 0.030) were independently associated with worse overall survival. Patients with gallbladder NETs had improved survival relative to those with gallbladder adenocarcinoma (p = 0.001), but significantly worse survival than patients with NETs from other gastrointestinal sites (p < 0.001). CONCLUSIONS:Primary gallbladder NETs are aggressive lesions that carry a worse prognosis than NETs of other gastrointestinal sites. Older age, positive margins, and large cell histology are associated with abbreviated survival after resection.
Authors: A Duffy; M Capanu; G K Abou-Alfa; D Huitzil; W Jarnagin; Y Fong; M D'Angelica; R P Dematteo; L H Blumgart; E M O'Reilly Journal: J Surg Oncol Date: 2008-12-01 Impact factor: 3.454
Authors: Yuman Fong; Lawrence Wagman; Mithat Gonen; James Crawford; William Reed; Richard Swanson; Charlie Pan; Jamie Ritchey; Andrew Stewart; Michael Choti Journal: Ann Surg Date: 2006-06 Impact factor: 12.969
Authors: Gyulnara G Kasumova; Omidreza Tabatabaie; Robert M Najarian; Mark P Callery; Sing Chau Ng; Andrea J Bullock; Robert A Fisher; Jennifer F Tseng Journal: Ann Surg Date: 2017-10 Impact factor: 12.969
Authors: Aileen C Johnson; Cecilia G Ethun; Yuan Liu; Alexandra G Lopez-Aguiar; Thuy B Tran; George Poultsides; Valerie Grignol; J Harrison Howard; Meena Bedi; T Clark Gamblin; Jennifer Tseng; Kevin K Roggin; Konstantinos Chouliaras; Konstantinos Votanopoulos; Darren Cullinan; Ryan C Fields; Keith A Delman; William C Wood; Kenneth Cardona; Shishir K Maithel Journal: J Am Coll Surg Date: 2018-06-12 Impact factor: 6.113
Authors: Arvind Dasari; Chan Shen; Daniel Halperin; Bo Zhao; Shouhao Zhou; Ying Xu; Tina Shih; James C Yao Journal: JAMA Oncol Date: 2017-10-01 Impact factor: 31.777
Authors: Yael Berger; Brianne J Sullivan; Natasha L Leigh; Eliahu Y Bekhor; Pooja Dhorajiya; Malary Mani; Deepa R Magge; Da Eun Cha; Umut Sarpel; Spiros P Hiotis; Daniel M Labow; Stephen C Ward; Benjamin J Golas; Noah A Cohen Journal: Ann Surg Oncol Date: 2022-04-18 Impact factor: 5.344
Authors: Reed I Ayabe; Michael M Wach; Samantha M Ruff; Laurence P Diggs; Sean P Martin; Timothy Wiemken; Leslie Hinyard; Jeremy L Davis; Carrie Luu; Jonathan M Hernandez Journal: J Surg Oncol Date: 2020-06-08 Impact factor: 2.885